CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer
© 2024. The Author(s)..
BACKGROUND: The evasion of the immune response by tumor cells through programmed death-ligand 1 (PD-L1) has been identified as a factor contributing to resistance to radioimmunotherapy in lung cancer patients. However, the precise molecular mechanisms underlying the regulation of PD-L1 remain incompletely understood. This study aimed to investigate the role of cyclin-dependent kinase-like 1 (CDKL1) in the modulation of PD-L1 expression and the response to radioimmunotherapy in lung cancer.
METHODS: The tumorigenic roles of CDKL1 were assessed via cell growth, colony formation, and EdU assays and an in vivo nude mouse xenograft model. The in vitro radiosensitization effect of CDKL1 was evaluated using a neutral comet assay, γH2AX foci formation analysis, and a clonogenic cell survival assay. The protein‒protein interactions were confirmed via coimmunoprecipitation and GST pulldown assays. The regulation of PD-L1 by CDKL1 was evaluated via chromatin immunoprecipitation (ChIP), real-time quantitative PCR, and flow cytometry analysis. An in vitro conditioned culture model and an in vivo C57BL/6J mouse xenograft model were developed to detect the activation markers of CD8+ T cells and evaluate the efficacy of CDKL1 overexpression combined with radiotherapy (RT) and an anti-PD-L1 antibody in treating lung cancer.
RESULTS: CDKL1 was downregulated and suppressed the growth and proliferation of lung cancer cells and increased radiosensitivity in vitro and in vivo. Mechanistically, CDKL1 interacted with the transcription factor YBX1 and decreased the binding affinity of YBX1 for the PD-L1 gene promoter, which consequently inhibits the expression of PD-L1, ultimately leading to the activation of CD8+ T cells and the inhibition of immune evasion in lung cancer. Moreover, the combination of CDKL1 overexpression, RT, and anti-PD-L1 antibody therapy exhibited the most potent antitumor efficacy against lung cancer.
CONCLUSIONS: Our findings demonstrate that CDKL1 plays a crucial role in regulating PD-L1 expression, thereby enhancing the antitumor effects of radioimmunotherapy. These results suggest that CDKL1 may be a promising therapeutic target for the treatment of lung cancer.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
---|---|
Enthalten in: |
Journal of experimental & clinical cancer research : CR - 43(2024), 1 vom: 22. März, Seite 89 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Zixuan [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s13046-024-03007-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370095693 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370095693 | ||
003 | DE-627 | ||
005 | 20240325235616.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240324s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s13046-024-03007-w |2 doi | |
028 | 5 | 2 | |a pubmed24n1347.xml |
035 | |a (DE-627)NLM370095693 | ||
035 | |a (NLM)38520004 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Zixuan |e verfasserin |4 aut | |
245 | 1 | 0 | |a CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.03.2024 | ||
500 | |a Date Revised 25.03.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s). | ||
520 | |a BACKGROUND: The evasion of the immune response by tumor cells through programmed death-ligand 1 (PD-L1) has been identified as a factor contributing to resistance to radioimmunotherapy in lung cancer patients. However, the precise molecular mechanisms underlying the regulation of PD-L1 remain incompletely understood. This study aimed to investigate the role of cyclin-dependent kinase-like 1 (CDKL1) in the modulation of PD-L1 expression and the response to radioimmunotherapy in lung cancer | ||
520 | |a METHODS: The tumorigenic roles of CDKL1 were assessed via cell growth, colony formation, and EdU assays and an in vivo nude mouse xenograft model. The in vitro radiosensitization effect of CDKL1 was evaluated using a neutral comet assay, γH2AX foci formation analysis, and a clonogenic cell survival assay. The protein‒protein interactions were confirmed via coimmunoprecipitation and GST pulldown assays. The regulation of PD-L1 by CDKL1 was evaluated via chromatin immunoprecipitation (ChIP), real-time quantitative PCR, and flow cytometry analysis. An in vitro conditioned culture model and an in vivo C57BL/6J mouse xenograft model were developed to detect the activation markers of CD8+ T cells and evaluate the efficacy of CDKL1 overexpression combined with radiotherapy (RT) and an anti-PD-L1 antibody in treating lung cancer | ||
520 | |a RESULTS: CDKL1 was downregulated and suppressed the growth and proliferation of lung cancer cells and increased radiosensitivity in vitro and in vivo. Mechanistically, CDKL1 interacted with the transcription factor YBX1 and decreased the binding affinity of YBX1 for the PD-L1 gene promoter, which consequently inhibits the expression of PD-L1, ultimately leading to the activation of CD8+ T cells and the inhibition of immune evasion in lung cancer. Moreover, the combination of CDKL1 overexpression, RT, and anti-PD-L1 antibody therapy exhibited the most potent antitumor efficacy against lung cancer | ||
520 | |a CONCLUSIONS: Our findings demonstrate that CDKL1 plays a crucial role in regulating PD-L1 expression, thereby enhancing the antitumor effects of radioimmunotherapy. These results suggest that CDKL1 may be a promising therapeutic target for the treatment of lung cancer | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a CDKL1 | |
650 | 4 | |a Lung cancer | |
650 | 4 | |a PD-L1 | |
650 | 4 | |a Radioimmunotherapy | |
650 | 4 | |a YBX1 | |
650 | 7 | |a Transcription Factors |2 NLM | |
650 | 7 | |a B7-H1 Antigen |2 NLM | |
650 | 7 | |a CDKL1 protein, human |2 NLM | |
650 | 7 | |a EC 2.7.11.22 |2 NLM | |
650 | 7 | |a Nerve Tissue Proteins |2 NLM | |
650 | 7 | |a Cyclin-Dependent Kinases |2 NLM | |
650 | 7 | |a EC 2.7.11.22 |2 NLM | |
650 | 7 | |a YBX1 protein, human |2 NLM | |
650 | 7 | |a Y-Box-Binding Protein 1 |2 NLM | |
700 | 1 | |a Xue, Huichan |e verfasserin |4 aut | |
700 | 1 | |a Li, Jinsong |e verfasserin |4 aut | |
700 | 1 | |a Zheng, Zhikun |e verfasserin |4 aut | |
700 | 1 | |a Liu, Zhiwei |e verfasserin |4 aut | |
700 | 1 | |a Dong, Xiaorong |e verfasserin |4 aut | |
700 | 1 | |a Wang, Hongbo |e verfasserin |4 aut | |
700 | 1 | |a Chen, Jing |e verfasserin |4 aut | |
700 | 1 | |a Xu, Shuangbing |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of experimental & clinical cancer research : CR |d 1994 |g 43(2024), 1 vom: 22. März, Seite 89 |w (DE-627)NLM08283427X |x 1756-9966 |7 nnns |
773 | 1 | 8 | |g volume:43 |g year:2024 |g number:1 |g day:22 |g month:03 |g pages:89 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13046-024-03007-w |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 43 |j 2024 |e 1 |b 22 |c 03 |h 89 |